Reuters logo
3 years ago
BRIEF-Ablynx signs exclusive license agreement with China's Eddingpharm
September 1, 2014 / 5:16 AM / 3 years ago

BRIEF-Ablynx signs exclusive license agreement with China's Eddingpharm

Sept 1 (Reuters) - Ablynx Nv :

* Signs exclusive license agreement with Eddingpharm to develop and commercialise its anti-TNFa Nanobody in greater China

* Granting Eddingpharm an exclusive, royalty-bearing license to develop and commercialise Ablynx's anti-TNFa Nanobody, ozoralizumab (atn-103)

* Will receive an upfront payment of 2 million euro, payable in two tranches

* Entitled to receive development and commercial milestone payments

* Plus tiered, double-digit royalties of up to 20 pct, based on annual net sales of ozoralizumab generated in greater China Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below